| Abstrakt: |
A study conducted at Chang Gung Memorial Hospital in Taoyuan, Taiwan, investigated the potential use of IKZF1 deletion as a marker for high-risk pediatric acute lymphoblastic leukemia (ALL). The study evaluated the prognostic impact of IKZF1 status in combination with minimal/measurable residual disease (MRD) in 412 newly diagnosed B-ALL patients aged 1-18. The results showed that IKZF1 deletion and IKZF1 independently predicted poorer outcomes in B-ALL, and the integration of IKZF1 and positive Day 15 MRD identified a subgroup of Philadelphia-negative B-ALL with a 50% risk of relapse. The study suggests that assessing IKZF1 alongside Day 15 MRD positivity can help identify patients at increased risk of adverse outcomes and potentially minimize overtreatment. [Extracted from the article] |
